Effects of hypocholesterolemic dietary and drug therapy on measures of dysphoric emotions

1998 ◽  
Vol 13 (6) ◽  
pp. 288-294
Author(s):  
Y Beigel ◽  
A Peleg ◽  
A Assali ◽  
I Nachshon
Keyword(s):  
Drug Therapy ◽  
Lipid Profile ◽  
Cholesterol Level ◽  
Negative Correlation ◽  
Dietary Modification ◽  
Cholesterol Reduction ◽  
Cholesterol Levels ◽  
Car Accidents ◽  
Dietary Period

SummaryThe question of whether hypocholesterolemic treatment is associated with increased mortality due to suicide, violence and car accidents is controversial and of great importance. We investigated the effect of hypocholesterolemic dietary and drug therapy on dysphoric emotions. Twenty-five hypocholesterolemic men were started on a 3-month dietary modification plan; those who showed unsatisfactory cholesterol reduction were given, in addition, a hypocholesterolemic drug for up to 1 year. Lipid profile and change in dysphoric emotions were measured. During the whole period, a negative correlation was found between cholesterol level and depression. During the dietary period, a significant improvement in depression and guilt with no change in lipid profile was noted. Drug therapy significantly reduced cholesterol levels, with a trend toward increased depression (after 3 months) and a significant increase in aggression and guilt (after 1 year). We conclude that changes in dysphoric emotions occurring during hypocholesterolemic therapy cannot be completely explained by the changes in cholesterol levels.

scholarly journals LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e029348 ◽  
Author(s):  
Faheem W Guirgis ◽  
Lauren Page Black ◽  
Martin Daniel Rosenthal ◽  
Morgan Henson ◽  
Jason Ferreira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Therapy ◽  
High Density Lipoprotein ◽  
Phase I ◽  
Cholesterol Level ◽  
Phase Ii ◽  
Lipid Emulsion ◽  
Density Lipoprotein ◽  
Control Group ◽  
Cholesterol Levels

IntroductionSepsis is a life-threatening, dysregulated response to infection. Both high-density lipoprotein and low-density lipoprotein cholesterol should protect against sepsis by several mechanisms; however, for partially unknown reasons, cholesterol levels become critically low in patients with early sepsis who experience poor outcomes. An anti-inflammatory lipid injectable emulsion containing fish oil is approved by the Food and Drug Administration as parenteral nutrition for critically ill patients and may prevent this decrease in serum cholesterol levels by providing substrate for cholesterol synthesis and may favourably modulate inflammation. This LIPid Intensive Drug therapy for Sepsis Pilot clinical trial is the first study to attempt to stabilise early cholesterol levels using lipid emulsion as a treatment modality for sepsis.Methods and analysisThis is a two-centre, phase I/II clinical trial. Phase I is a non-randomised dose-escalation study using a Bayesian optimal interval design in which up to 16 patients will be enrolled to evaluate the safest and most efficacious dose for stabilising cholesterol levels. Based on phase I results, the two best doses will be used to randomise 48 patients to either lipid injectable emulsion or active control (no treatment). Twenty-four patients will be randomised to one of two doses of the study drug, while 24 control group patients will receive no drug and will be followed during their hospitalisation. The control group will receive all standard treatments mandated by the institutional sepsis alert protocol. The phase II study will employ a permuted blocked randomisation technique, and the primary endpoint will be change in serum total cholesterol level (48 hours − enrolment). Secondary endpoints include change in cholesterol level from enrolment to 7 days, change in Sequential Organ Failure Assessment score over the first 48 hours and 7 days, in-hospital and 28-day mortality, lipid oxidation status, inflammatory biomarkers, and high-density lipoprotein function.Ethics and disseminationInvestigators are trained and follow good clinical practices, and each phase of the study was reviewed and approved by the institutional review boards of each institution. Results of each phase will be disseminated through presentations at national meetings and publication in peer-reviewed journals. If promising, data from the pilot study will be used for a larger, multicentre, phase II clinical trial.Trial registration numberNCT03405870.

scholarly journals Lipid Profiles as Markers for the Severity of Liver Diseases in Cirrhotic Patients

2021 ◽  
Vol 11 (1) ◽  
pp. 93-98
Author(s):  
Rehab Badawi ◽  
Mohamed Zakaria Abu Rahma ◽  
Haidi K. Ramadan ◽  
Shaimaa Soliman ◽  
Dina A. Mohareb ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Lipid Profile ◽  
Cholesterol Level ◽  
Negative Correlation ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Significant Negative Correlation ◽  
Low Density ◽  
Lymphocyte Ratio ◽  
Cirrhotic Patients

Background Liver cirrhosis is a diffuse process in which the anatomical structure and function of the liver are disturbed. Lipid metabolism occurs mainly in the hepatocytes. In liver cirrhosis, it is expected to detect abnormal lipid profile and abnormal neutrophil to lymphocyte ratio due to necro-inflammation and hepatocyte dysfunction. This study aimed to estimate the lipid profile in patients with liver cirrhosis and to assess its relation to the severity of the liver disease based on Child-Pugh Turcotte score and Neutrophil to Lymphocyte Ratio (NLR). Methods: This study included 500 cirrhotic patients. All patients are subjected to history taking, clinical examination, liver and renal function tests, lipid profile, and also abdomino-pelvic ultrasound. Child -Pugh score, fibrosis-4 score (FIB4), and neutrophil and platelet lymphocyte ratio were calculated. Results: A total of 500 patients were enrolled in this study; 12 patients were excluded (two patients were on the immunosuppressive drug, three patients had body mass index (BMI) >30, and seven patients took lipid-lowering drugs). Cholesterol level was significantly higher in patients with Child- Score A than B and C. Cholesterol, Low-Density Lipoprotein (LDL), and very-low-density lipoprotein (VLDL) cholesterol were significantly higher in Child B than C. A significant negative correlation was found between cholesterol level and each of FIB4 and NLR ratios. Conclusion: There was a significant negative correlation between the severity of liver cirrhosis and lipid profiles (except triglyceride), FIB4 and NLR ratio.

scholarly journals An audit to assess whether patients under the care of a community mental health team who are taking clozapine are having their lipid profile checked annually and are given lifestyle advice and have had a QRISK3 assessment

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S89-S89
Author(s):  
Elisabeth Linley-Adams ◽  
Bethan Harris
Keyword(s):  
Mental Health ◽  
Community Mental Health ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Cholesterol Level ◽  
Lifestyle Advice ◽  
Community Mental Health Team ◽  
Mental Health Team ◽  
Health Team ◽  
Cholesterol Levels

Aims‘All cause’ mortality is higher among patients with serious mental illness than the general population and a significant contributor from this is cardiovascular disease. Mean triglyceride levels have been shown to double and cholesterol levels to increase by at least 10% after 5 years’ treatment with clozapine. NICE guidelines state all patients should have their lipids measured at baseline, 3 months after starting treatment with a new antipsychotic, and then annually.The first aim of our audit was to identify whether patients who had been on clozapine for at least 3 months from our community mental health team (CMHT) who were not taking cholesterol lowering medication are having their lipid profile checked annually. The second aim was to see whether these patients have high total cholesterol levels and whether they had had a documented discussion about exercise, diet or lifestyle and a QRISK3 assessment.MethodWe constructed a list of 56 patients who were taking clozapine from the CMHT. We excluded 17 patients who were on cholesterol lowering medication and would have excluded any patients who had been on clozapine for less than 3 months. We then looked at whether the patients had had a lipid profile and identified patients with a cholesterol level >5.0 to indicate a ‘high cholesterol level.’ We then searched through the last year of each of the patient's case notes to see whether they had had a QRISK assessment or lifestyle advice by searching for the words ‘diet, exercise, lifestyle and QRISK’.Result36 of the 39 (92%) patients had lipid levels checked in the last 12 months. 21 of the 39 (54%) patients had a cholesterol over 5.0. 9 of the 39 (23%) patients had a documented discussion regarding lifestyle, diet or exercise in the last year. 0 of the 39 (0%) patients had a documented QRISK3 assessment.ConclusionMost (92%) patients from the CMHT had their lipid profile checked in the last year. 54% had total cholesterol level over 5.0. Only a small proportion (23%) had documented lifestyle discussion and none of the patients had a QRISK3 assessment. The results will be presented to the CMHT and we will organise teaching on giving lifestyle advice and QRISK3 assessments.

Pengaruh Pemberian Terapi Oksigen Hiperbarik Terhadap Kadar Kolesterol Total Pada Tikus Putih (Rattus novergicus) Jantan Galur Wistar Yang Di Induksi Diet Tinggi Lemak

2018 ◽  
Vol 16 (1) ◽  
pp. 1 ◽  
Author(s):  
AZRUL HILDAN SAFRIZAL
Keyword(s):  
Cardiovascular Disease ◽  
Total Cholesterol ◽  
Cholesterol Level ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
High Fat Diet ◽  
Oxygen Therapy ◽  
Total Cholesterol Level ◽  
High Fat ◽  
Cholesterol Levels

<p>The pattern and lifestyle of today's society with the presence of an interner facility makes people spend more time sitting out than on exercise and increased consumption of high-fat foods may increase the risk of cardiovascular disease. An effective therapy is needed in preventing the occurrence of cardiovascular disease. Hyperbaric oxygen now starts to develop for the treatment of several diseases, which in turn can increase the gene forming antioxidant enzymes and ROS. To determine effect of hyperbaric oxygen therapy on total cholesterol levels of wistar white rats (Rattusnovergicus) induced bye high fat. The study was carried out in an expeative post test only group control of three groups. One group is given standard feed. All groups induced high-fat diet and standard feed. Of the two groups induced, one group was given hyperbaric oxygen therapy with a dose of 3 x 30 minutes for six days on day 7 at a blood test to determine total cholesterol levels<strong>. </strong>One way Anova parametric statistic test showed that p = 0.007 &lt; α proved hypothesis that hyperbaric oxygen therapy giving effect to total cholesterol level of white mice of jantangalurist rings induced by high fat diet. Total cholesterol was significantly different between K (-) and K (+) and between K (-) and P. It was found that hyperbaric oxygen therapy had an effect on total cholesterol level dose of 3x30 minutes for six days.</p>

SISTEM PAKAR MENU MAKANAN SEHAT BAGI PENDERITA KOLESTEROL DENGAN METODE FORWARD CHAINING

2017 ◽  
Vol 3 (2) ◽  
pp. 72
Author(s):  
Gusnita Darmawati
Keyword(s):  
Expert System ◽  
Cholesterol Level ◽  
Blood Group ◽  
Healthy Food ◽  
Healthy Diet ◽  
Blood Type ◽  
Forward Chaining ◽  
Cholesterol Levels ◽  
Microsoft Office ◽  
Visual Basic 6.0

<p>Penelitian ini membangun suatu sistem pakar untuk menentukan menu makanan sehat berdasarkan golongan darah dan tingkat kadar kolesterol pasien dengan metode Forward Chaining. Tujuan untuk membantu orang awam dalam menentukan menu makanan sehat untuk pasien kolesterol. Sistem ini menganalisa masalah penentuan menu makanan sehat berdasarkan golongan darah dan tingkat kadar kolesterol pasien. Hasil yang diperoleh dari sitem pakar ini adalah berupa informasi makanan sehat yang akan dikonsumsi oleh pasien kolesterol dengan jenis golongan darah dan tingkat kadar kolesterol yang berbeda. Analisa dilakukan dengan cara mengetahui jenis golongan darah dan tingkat kadar kolesterol pasien yang ditampilkan oleh program sistem pakar ini, rancangan sistem ini menggunakan inference forward chaining, dengan implementasi sistem menggunakan sistem database Microsoft Office Access dan bahasa pemrograman Visual Basic 6.0. Dari rancangan aplikasi sistem pakar yang dibuat, maka orang awam yang memderita kolesterol dapat menentukan menu makanan sehat untuk di konsumsi berdasarkan golongan darah dan tingkat kadar kolesterol dengan menjalankan aplikasi sistem pakar.</p><p><em><br /></em></p><p><em><em>This study builds an expert system to determine the healthy food menu based on blood type and cholesterol levels of patients with Forward Chaining method. The goal is to help the layman in determining a healthy diet for cholesterol patients. This system analyzes the problem of determining healthy food menu based on blood group and patient cholesterol level. The results obtained from this expert system is in the form of healthy food information that will be consumed by cholesterol patients with the type of blood group and different cholesterol levels. From the design of expert system applications created, the layman who memderita cholesterol can determine the healthy diet to be consumed by blood type and cholesterol level by running an expert system application.<br /> <br /> </em></em></p>

scholarly journals Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Andrea Giacomelli ◽  
Federico Conti ◽  
Laura Pezzati ◽  
Letizia Oreni ◽  
Anna Lisa Ridolfo ◽  
...  
Keyword(s):  
Body Weight ◽  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Risk Score ◽  
Rank Test ◽  
People Living With Hiv ◽  
Cholesterol Levels ◽  
Signed Rank Test ◽  
Living With Hiv

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in a cohort of people living with HIV/AIDS (PLWH) under effective ART. Methods All PLWH aged above 18 years on antiretroviral treatment with an HIV-RNA < 50 cp/mL at the time of the switch to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG were retrospectively included in the analysis. Framingham risk score modification after 12 months from the switch such as lipid profile and body weight modification were assessed. The change from baseline to 12 months in mean cardiovascular risk and body weight in each of the STR’s group were assessed by means of Wilcoxon signed-rank test whereas a mixed regression model was used to assess variation in lipid levels. Results Five-hundred and sixty PLWH were switched to an STR regimen of whom 170 (30.4%) to TAF/FTC/EVG/cobi, 191 (34.1%) to TAF/FTC/RPV and 199 (35.5%) to ABC/3TC/DTG. No difference in the Framingham cardiovascular risk score was observed after 12 months from the switch in each of the STR’s groups. No significant overtime variation in mean total cholesterol levels from baseline to 12 months was observed for PLWH switched to ABC/3TC/DTG [200 (SD 38) mg/dl vs 201 (SD 35) mg/dl; p = 0.610] whereas a significant increment was observed in PLWH switched to TAF/FTC/EVG/cobi [192 (SD 34) mg/dl vs 208 (SD 40) mg/dl; p < 0.0001] and TAF/FTC/RPV [187 (SD 34) mg/dl vs 195 (SD 35) mg/dl; p = 0.027]. In addition, a significant variation in the mean body weight from baseline to 12 months was observed in PLWH switched to TAF/FTC/EVG/cobi [72.2 (SD 13.5) kilograms vs 74.6 (SD 14.3) kilograms; p < 0.0001] and TAF/FTC/RPV [73.4 (SD 11.6) kilograms vs 75.6 (SD 11.8) kilograms; p < 0.0001] whereas no difference was observed in those switched to ABC/3TC/DTG [71.5 (SD 12.8) kilograms vs 72.1 (SD 12.6) kilograms; p = 0.478]. Conclusion No difference in the cardiovascular risk after 1 year from the switch to these STRs were observed. PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch.

Tracking of Serum Cholesterol Levels in a Multiracial Sample of Preschool Children

PEDIATRICS ◽  
1992 ◽  
Vol 90 (1) ◽  
pp. 80-86 ◽  
Author(s):  
David S. Freedman ◽  
Tim Byers ◽  
Karen Sell ◽  
Sarah Kuester ◽  
Eva Newe1l ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Cholesterol Level ◽  
Initial Level ◽  
Total Cholesterol Level ◽  
Relative Weight ◽  
Cholesterol Levels ◽  
Final Measurement ◽  
Subsequent Measurement ◽  
Initial Measurement

The relation of an initial measurement of serum total cholesterol to subsequent levels over a (mean) 13-month interval was examined in a multiracial (white, Hispanic, American Indian, and black) sample of 1680 one- to four-year-olds. Although the relation of the initial level to the final measurement (r = .54) did not vary by race, sex, relative weight, or changes in relative weight, the association increased with age at the time of the initial measurement (eg, r .64 among 4-year-olds). Based on the initial and final total cholesterol determinations, the within-person standard deviation was 21 mg/dL and the coefficient of variation was 13%. Although the final total cholesterol level was within 5 mg/dL of the initial level for 18% of the children, the two determinations differed by ≥25 mg/dL for about 35% of the children and by ≥50 mg/dL for about 8%. Of the 149 children who had an initial cholesterol level ≥200 mg/dL, 34% (about five times the expected number) had a follow-up level that was similarly elevated whereas 25% had a subsequent measurement below 170 mg/dL. The results indicate that although an initial cholesterol level in early life is moderately predictive of subsequent levels, it may be difficult to interpret a single total cholesterol determination because of substantial within-person variability.

Cholesterol Among Children of Men With Myocardial Infarction

PEDIATRICS ◽  
1976 ◽  
Vol 58 (2) ◽  
pp. 211-217
Author(s):  
Charles H. Hennekens ◽  
Mary Jane Jesse ◽  
Barbara E. Klein ◽  
Janet E. Gourley ◽  
Sidney Blumenthal
Keyword(s):  
Myocardial Infarction ◽  
Family History ◽  
Cholesterol Level ◽  
Coronary Disease ◽  
Plasma Cholesterol ◽  
Age Groups ◽  
Healthy Men ◽  
Cholesterol Levels ◽  
Premature Myocardial Infarction ◽  
The Mean

Plasma cholesterol levels were obtained on 90 children of 39 men with premature myocardial infarction and 86 children of 39 healthy men. The mean cholesterol among children of affected men (195.1 mg/100 ml) was higher than among children of healthy men (176.6 mg/100 ml) (P = .009). Higher mean levels were demonstrable at each of nine age groups from 1 to 21 years (P = .004). Levels greater than 230 mg/100 ml were found in 16.7% of children of affected fathers and 4.7% of children of healthy fathers, a ratio of 3.6 to 1 (P = .01). These findings are compatible with the hypothesis that elevated childhood cholesterol level offers a mechanism whereby family history predicts coronary disease. A dip in cholesterol during adolescence, a finding that varies with population studied, was demonstrable among children of both affected and healthy men.

An Assessment of Serum Cholesterol level and BMI in Women: Study in Several Private Chambers in Mymensingh

2019 ◽  
Vol 8 (2) ◽  
pp. 4-9
Author(s):  
Nahid Bintay Ansary ◽  
Arup Ratan Paul ◽  
Md Mahamudur Rahman ◽  
Maria Hussain ◽  
Rubiat Naznin
Keyword(s):  
Cardiovascular Disease ◽  
Health Status ◽  
Cholesterol Level ◽  
Serum Cholesterol ◽  
Serum Cholesterol Level ◽  
Normal Weight ◽  
Cholesterol Levels ◽  
Increased Risk ◽  
The Mean ◽  
Study Participants

The increased risk of cardiovascular disease associated with higher serum cholesterol levels in middle-aged persons has been established, but there have been few studies conducted regarding the issues in Mymensingh. For evaluation of serum cholesterol and BMI in women of Mymensingh, across-sectional studywas conducted in several private chambers in the districts of Mymensingh, Bangladesh during the period from January 2017 to December 2017. A total of 48 Female patients participated in the study. In the study, participants were aged between 18 to 29 years of age. The study suggested that the serum cholesterol was below 4.99 were 15(31.25%), 5.00 to 6.49 were 13(26.08%) and above 6.50 were 20 (41.67%), the Mean ± SD was 4.45 (0.76). The health status according to BMI showed that 12.50% (n=6) of the participants were underweight <18.49, majority 50.00% (n=24) of the population were from normal weight range (18.5-24.9), 16.67% (n=8) of the participants were overweight and 20.83 %( n=10) of the participants were obese >30. The Mean ± SD was 18.93± (3.68). Measurement of BMI and Serum Cholesterol levels can help doctors to treat patients properly for reducing the burden of death in our country. CBMJ 2019 July: Vol. 08 No. 02 P: 4-9

Abstract P111: Comparative Efficacy Of Bisoprolol Compared To Other Selective Beta-1 Blockers In Patients With Hypertension - A Systematic Review And Meta-analysis Of Observational Studies

Hypertension ◽  
2021 ◽  
Vol 78 (Suppl_1) ◽  
Author(s):  
Uday M Jadhav ◽  
Tiny Nair ◽  
SANDEEP BANSAL ◽  
Saumitra Ray
Keyword(s):  
Lipid Profile ◽  
Observational Studies ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Clinical Decision ◽  
Cochrane Library ◽  
Favourable Effect ◽  
Pooled Data ◽  
Cholesterol Levels

Introduction: Selective beta-1 blockers (s-BBs) are used in the management of hypertension (HT) in specific subsets. Studies comparing the potency of blood pressure (BP) lowering with different s-BBs are sparse. The objective of this meta-analysis was to evaluate the efficacy of bisoprolol compared to other s-BBs (Atenolol, Betaxolol, Esmolol, Acebutolol, Metoprolol, Nebivolol) in HT patients by examining their effect on BP, heart rate (HR) and metabolic derangements, by examining the evidences reported in observational studies. Methods: Electronic databases like PubMed, EMBASE, Cochrane Library, Clinicaltrials.gov, Surveillance, Epidemiology and End Results Program and 12 PV databases were systematically searched from inception to October 2019. Observational studies that compared bisoprolol with other s-BBs in patients with HT were evaluated in accordance with the PRISMA guidelines. Pooled data were calculated using random-effects model for meta-analysis in terms of mean difference (MD) and 95% confidence interval (95% CI) for each outcome. Outcomes of interest were BP, HR and lipid profile. Results: Four observational studies which compared bisoprolol with other s-BBs (nebivolol and atenolol) were included in this meta-analysis. Significant reduction was observed in office diastolic BP [MD: -1.70; 95% CI: -2.68,-0.72; P <0.01] among arterial HT patients treated with bisoprolol for 26 weeks (w) compared to those treated with other s-BBs. HT patients treated with bisoprolol for 26 w showed significant reduction in HR [MD: -2.20; 95% CI: -3.57,-0.65; P <0.01] and office HR [MD: -2.55; 95% CI: -3.57,-1.53; P <0.01] than other s-BBs. HDL cholesterol levels increased significantly in essential HT patients treated with bisoprolol at 26 w [MD: 7.17; 95% CI: 1.90,12.45; P <0.01], 78 w [MD: 11.70; 95% CI: 4.49,18.91; P <0.01] and 104 w [MD: 10.20, 95% CI: 4.49,18.91; P <0.01] compared to other s-BBs. Conclusion: Our results suggests that bisoprolol is superior to other s-BBs in reducing BP and HR. Bisoprolol also had a favourable effect on lipid profile shown by increase in HDL cholesterol. This meta-analysis emphasizes the efficacy of bisoprolol over other s-BBs, which aids clinical decision making in treatment of patients with HT.

Sign in / Sign up

Export Citation Format

Share Document